clinical trial · NCT07404644
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
Takeda·—·recruiting·n = 13
Von Willebrand Disease (vWD)vonicog alfa (rVWF)
brief summary
This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa (rVWF). During the study, pediatric participants with vWD will be administered with rVWF under routine normal practice. The investigators will evaluate adverse events due to rVWF for 1 year from the start of drug administration. The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.
started
Feb 19, 2026
primary completion
May 30, 2031
completion
May 30, 2031
last updated
Feb 23, 2026
official title
Vonvendi Intravenous Specified Drug Use-results Survey "Pediatric Administration"
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol